A Phase 2 interventional study of dabigatran etexilate low dose and warfarin 5mg in Thromboembolism and Heart Valve Prosthesis, sponsored by Boehringer Ingelheim. Terminated at 30 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-07-11.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Thromboembolism by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Thromboembolism · Boehringer Ingelheim.
Among the 12 studies in Thromboembolism by Boehringer Ingelheim, this one is the only one that started in 2011, is the only one in phase 2, and was the 10th registered.
288 studies on the registry are indexed under Thromboembolism; 42 are open to participants now.
Browse Thromboembolism studies →None of the 12 studies in Thromboembolism by Boehringer Ingelheim is open now. The open studies under Thromboembolism, anywhere →
Of the 32 Thromboembolism studies recruiting now, 23 (72%) set no upper age limit and 4 (13%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2011.
This study's enrollment of 158 is close to the median of 173 across 155 interventional studies indexed under Thromboembolism.
Median enrollment 2,577 across the 8 interventional studies, 239 across the 4 observational. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Thromboembolism by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To collect additional data relating to safety and indicators of efficacy for patients who have participated in the 1160.113 study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Patient dose determined by dose allocated in 1160.113 and CrCl levels
Drug: dabigatran etexilate low dose · Drug: dabigatran etexilate intermediate dose · Drug: dabigatran etexilate high dose
warfarin doses to maintain INR levels
Drug: warfarin 5mg · Drug: warfarin 1mg · Drug: warfarin 3mg
active treatment (low)
comparator warfarin
active treatment (medium)
comparator warfarin
active treatment (high)
comparator warfarin
Percentage of Patients With Any Adverse Event (AE)
Percentage of patients with Adverse Events. Prespecified clinical outcome events were not recorded as Adverse Events.
Time frame: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)
Percentage of Patients With AEs Leading to Discontinuation of Trial Drug
Percentage of patients with Adverse Events leading to discontinuation of trial drug. Prespecified clinical outcome events were not recorded as Adverse Events.
Time frame: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)
Percentage of Patients With Serious AEs
Percentage of patients with Serious Adverse Events (SAE). Prespecified clinical outcome events were not recorded as Adverse Events.
Time frame: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)
Percentage of Deaths, Venous Thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attacks (TIA), Strokes, Systemic Embolism, and Valve Thrombosis.
Clinical efficacy outcome events presented are: Death, Venous thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attack (TIA), Stroke, Systemic embolism and Valve thrombosis
Time frame: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)
| Milestone | Dabigatran Etexilate (DE) | Warfarin |
|---|---|---|
| Started | 99 | 59 |
| Completed | 95 | 58 |
| Not completed | 4 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
Percentage of patients with Adverse Events. Prespecified clinical outcome events were not recorded as Adverse Events.
| percentage of participants | Dabigatran Etexilate (DE) | Warfarin |
|---|---|---|
| Percentage of Patients With Any Adverse Event (AE) | 39.4 | 37.3 |
Percentage of patients with Adverse Events leading to discontinuation of trial drug. Prespecified clinical outcome events were not recorded as Adverse Events.
| percentage of participants | Dabigatran Etexilate (DE) | Warfarin |
|---|---|---|
| Percentage of Patients With AEs Leading to Discontinuation of Trial Drug | 5.1 | 1.7 |
Percentage of patients with Serious Adverse Events (SAE). Prespecified clinical outcome events were not recorded as Adverse Events.
| percentage of participants | Dabigatran Etexilate (DE) | Warfarin |
|---|---|---|
| Percentage of Patients With Serious AEs | 3.0 | 6.8 |
Clinical efficacy outcome events presented are: Death, Venous thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attack (TIA), Stroke, Systemic embolism and Valve thrombosis
| percentage of participants | Dabigatran Etexilate (DE) | Warfarin |
|---|---|---|
| Death | 0.0 | 1.7 |
| Venous thromboembolism | 0.0 | 0.0 |
| Myocardial Infarction | 1.0 | 0.0 |
| Transient Ischaemic Attack | 1.0 | 0.0 |
| Stroke | 3.0 | 0.0 |
| Systemic embolism | 0.0 | 0.0 |
| Valve thrombosis | 2.0 | 0.0 |
Collected over From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran Etexilate | — | 3/99 (3%) | 5/99 (5.1%) |
| Warfarin | — | 4/59 (6.8%) | 4/59 (6.8%) |
| Event | Dabigatran Etexilate | Warfarin |
|---|---|---|
| EpilepsyNervous system disorders | 0/99 | 1/59 |
| Atrial fibrillationCardiac disorders | 0/99 | 1/59 |
| Fibrocystic breast diseaseReproductive system and breast disorders | 0/99 | 1/59 |
| Chest painGeneral disorders | 0/99 | 1/59 |
| CellulitisInfections and infestations | 1/99 | 0/59 |
| Cardiac failure congestiveCardiac disorders | 1/99 | 0/59 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/99 | 0/59 |
| CholecystitisHepatobiliary disorders | 1/99 | 0/59 |
| Renal colicRenal and urinary disorders | 1/99 | 0/59 |
| Event | Dabigatran Etexilate | Warfarin |
|---|---|---|
| HypertensionVascular disorders | 5/99 | 4/59 |
Treated set (TRT): The TRT comprised all patients who were documented to have taken at least 1 dose of study drug
| Age, Continuous(years) | Dabigatran Etexilate (DE) | Warfarin | Total |
|---|---|---|---|
| Mean | 57.8 ± 8.0 | 56.1 ± 10.1 | 57.2 ± 8.8 |
| Sex: Female, Male(Participants) | Dabigatran Etexilate (DE) | Warfarin | Total |
|---|---|---|---|
| Female | 37 | 19 | 56 |
| Male | 62 | 40 | 102 |
The record gives a start of Dec 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.